Safe use of right lobe live donor livers with up to 20% macrovesicular steatosis without compromising donor safety and recipient outcome.
The principle in right lobe living donor liver transplantation (RLLDLT) is to use "near-perfect" grafts to maximise recipient benefit with minimal donor risk. Whether, and what degree of graft macrovesicular steatosis is safe for both recipient and donor, is debatable. We compared donor and recipient outcomes in 623 primary RLLDLT's, using grafts with (Group A;10-20% steatosis, n=92), and without (Group B; <10%, n=531) significant macrovesicular steatosis, on pre or intra operative biopsy. Group A donors had higher BMI, transaminases, fasting blood sugar, triglyceride, and low density lipoprotein level, and lower high density lipoprotein, and liver attenuation index (LAI) on CT scan, and similar future liver remnant (FLR). Mean post operative day [POD7] aspartate aminotransferase [AST] (61.13 + 24.77 vs. 73.17 + 53.71 IU/L;p=0.04), and prothrombin time-international normalized ratio [PT-INR] (1.16 + 0.36 vs. 1.28 + 0.24;p=0.0001) were lower in Group A donors. POD 3/7 total bilirubin [TB], and alanine aminotransferase [ALT], POD3 AST and PT-INR; postoperative morbidity (Dindo-Clavien >3b), hospital stay were similar in both groups. Recipients in both groups had similar age, MELD score. RL graft weight (764.8 + 145.46 vs. 703.24 + 125.53 grams;p<0.0001), and GRWR (1.09 + 0.29 vs. 1.00 + 0.21;p=0.0004) were higher in Group A. All biochemical parameters at POD3/7, as well as hospital stay, 30-day mortality were similar in recipients of both groups, even after matching both groups for age, MELD and GRWR. Use of well selected RL grafts (adequate FLR in donor, GRWR in recipient) with up to 20% macrovesicular steatosis, does not compromise graft function and outcomes, and is safe for the donor.